MX2017014192A - Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa. - Google Patents

Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa.

Info

Publication number
MX2017014192A
MX2017014192A MX2017014192A MX2017014192A MX2017014192A MX 2017014192 A MX2017014192 A MX 2017014192A MX 2017014192 A MX2017014192 A MX 2017014192A MX 2017014192 A MX2017014192 A MX 2017014192A MX 2017014192 A MX2017014192 A MX 2017014192A
Authority
MX
Mexico
Prior art keywords
neurodegenerative disease
compositions
treating
methods
phenylsulfonyl
Prior art date
Application number
MX2017014192A
Other languages
English (en)
Inventor
M Lewis Bryan
Tim Friedhoff Lawrence
Clement PISCITELLI Stephen
Kishnani Kunal
Ramaswamy Shankar
Ramaswamy Geetha
Rhodes Melissa
Original Assignee
Axovant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axovant Sciences Gmbh filed Critical Axovant Sciences Gmbh
Publication of MX2017014192A publication Critical patent/MX2017014192A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente solicitud se refiere a nuevos usos de antagonistas del receptor 5-HT6, específicamente 3- fenilsulfoni1-8-piperazinil -lil-guinolina o sales farmacéuticamente aceptables, hidratos, solvatos, o polimorfos, de la misma, y a la combinación de antagonistas del receptor 5-HT6, específicamente 3-fenilsulfoni1-8-piperazinil-lil-guinolina o sales farmacéuticamente aceptables, hidratos, solvatos, o polimorfos, de la misma, con otros agentes terapéuticos para el tratamiento de una enfermedad neurodegenerativa.
MX2017014192A 2015-05-07 2016-05-06 Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa. MX2017014192A (es)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US201562158422P 2015-05-07 2015-05-07
US201562162068P 2015-05-15 2015-05-15
US201562162060P 2015-05-15 2015-05-15
US201562162138P 2015-05-15 2015-05-15
US201562162193P 2015-05-15 2015-05-15
US201562165034P 2015-05-21 2015-05-21
US201562167986P 2015-05-29 2015-05-29
US201562168246P 2015-05-29 2015-05-29
US201562169414P 2015-06-01 2015-06-01
US201562182225P 2015-06-19 2015-06-19
US201562189089P 2015-07-06 2015-07-06
US201562191189P 2015-07-10 2015-07-10
US201562201494P 2015-08-05 2015-08-05
US201562201513P 2015-08-05 2015-08-05
US201562239530P 2015-10-09 2015-10-09
US201562251534P 2015-11-05 2015-11-05
US201562256349P 2015-11-17 2015-11-17
US201562261115P 2015-11-30 2015-11-30
US201662289162P 2016-01-29 2016-01-29
US201662289643P 2016-02-01 2016-02-01
PCT/US2016/031367 WO2016179569A1 (en) 2015-05-07 2016-05-06 Compositions and methods of treating a neurodegenerative disease

Publications (1)

Publication Number Publication Date
MX2017014192A true MX2017014192A (es) 2018-08-01

Family

ID=57217933

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017014192A MX2017014192A (es) 2015-05-07 2016-05-06 Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa.
MX2017014191A MX2017014191A (es) 2015-05-07 2016-05-06 Metodos de tratamiento de una enfermedad neurodegenerativa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017014191A MX2017014191A (es) 2015-05-07 2016-05-06 Metodos de tratamiento de una enfermedad neurodegenerativa.

Country Status (12)

Country Link
US (1) US20160324852A1 (es)
EP (2) EP3291815A4 (es)
JP (2) JP2018519358A (es)
KR (2) KR20180022661A (es)
CN (2) CN107847499A (es)
AU (2) AU2016258198A1 (es)
CA (2) CA2985366A1 (es)
HK (1) HK1245078A1 (es)
IL (2) IL255421A0 (es)
MX (2) MX2017014192A (es)
NO (2) NO20171941A1 (es)
WO (2) WO2016179566A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1558582T3 (pl) 2003-07-22 2006-05-31 Arena Pharm Inc Diarylowe i aryloheteroarylowe pochodne mocznika jako modulatory receptora serotoninowego 5-HT2A użyteczne w profilaktyce i w leczeniu zaburzeń związanych z tym receptorem
WO2009074607A1 (en) 2007-12-12 2009-06-18 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
KR20180022792A (ko) 2015-06-12 2018-03-06 엑소반트 사이언시즈 게엠베하 렘 수면 행동 장애의 예방 및 치료에 유용한 디아릴 및 아릴헤테로아릴 우레아 유도체
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
AU2016291673A1 (en) 2015-07-15 2018-01-25 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
US20210346374A1 (en) * 2016-10-03 2021-11-11 Suven Life Sciences Limited Pharmaceutical compositions of 5-ht6 receptor antagonist
MX2019005594A (es) * 2016-11-15 2019-07-04 H Lundbeck As Agentes, usos y metodos para el tratamiento de la sinucleinopatia.
WO2018102824A1 (en) * 2016-12-02 2018-06-07 Axovant Sciences Gmbh Methods for treating neurodegenerative disease
PT3630098T (pt) * 2017-05-24 2021-04-21 H Lundbeck As Combinação de um antagonista do receptor 5-ht6 e de um inibidor de acetilcolinesterase para utilização no tratamento da doença de alzheimer numa subpopulação de pacientes portadores de alelos apoe4
KR20200010211A (ko) 2017-06-01 2020-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 Pde9 저해제를 포함하는 약제학적 조성물
EP3628315A1 (en) * 2018-09-28 2020-04-01 Université de Caen Normandie Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases
HRP20220739T1 (hr) * 2020-05-04 2022-08-19 Bioprojet Pharma Upotreba dopaminskih d3 djelomičnih agonista za liječenje poremećaja središnjeg živčanog sustava
CN116457019A (zh) * 2020-07-10 2023-07-18 艾吉因生物股份有限公司 GABAAα5激动剂的多晶型物及其在治疗认知损害中的使用方法
CN112587534A (zh) * 2020-12-23 2021-04-02 佑嘉(杭州)生物医药科技有限公司 阿伦酸在制备治疗肝纤维化药物中的用途
WO2023128900A1 (en) * 2021-12-30 2023-07-06 Pharmactive Ilac Sanayi Ve Ticaret A.S. Pharmaceutical compositions comprising pimavanserin as active ingredient and relevant excipients
WO2024040167A2 (en) * 2022-08-18 2024-02-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Selective mc4r ligand for treating obesity and cognitive loss

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2479786C (en) * 2002-03-27 2011-11-29 Glaxo Group Limited Quinoline derivatives and their use as 5-ht6 ligands
EP2243475B1 (en) * 2005-04-06 2016-01-13 Adamas Pharmaceuticals, Inc. Combination of memantine and donepezil for treatment of CNS disorders
PE20071143A1 (es) * 2006-01-13 2008-01-20 Wyeth Corp Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
CA2658959A1 (en) * 2006-06-23 2007-12-27 Laboratorios Del Dr. Esteve, S.A. Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
AR061637A1 (es) * 2006-06-26 2008-09-10 Epix Delaware Inc Composiciones y metodos de tratamiento de trastornos del snc
WO2009074607A1 (en) * 2007-12-12 2009-06-18 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
TR201805216T4 (en) * 2008-10-28 2018-06-21 Arena Pharm Inc COMPOSITIONS OF A USEFUL 5-HT2A SEROTONINE RECEPTOR MODULATOR FOR THE TREATMENT OF RELATED DISORDERS
US20110251239A1 (en) * 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
JO3459B1 (ar) * 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر

Also Published As

Publication number Publication date
JP2018515607A (ja) 2018-06-14
CN107847499A (zh) 2018-03-27
IL255423A0 (en) 2017-12-31
EP3291815A4 (en) 2019-01-16
EP3291815A1 (en) 2018-03-14
WO2016179569A1 (en) 2016-11-10
CA2985370A1 (en) 2016-11-10
JP2018519358A (ja) 2018-07-19
US20160324852A1 (en) 2016-11-10
WO2016179566A1 (en) 2016-11-10
NO20171941A1 (en) 2017-12-05
EP3291816A4 (en) 2019-01-02
IL255421A0 (en) 2017-12-31
AU2016256923A1 (en) 2017-11-23
KR20180021693A (ko) 2018-03-05
EP3291816A1 (en) 2018-03-14
CN107949386A (zh) 2018-04-20
KR20180022661A (ko) 2018-03-06
MX2017014191A (es) 2018-08-01
CA2985366A1 (en) 2016-11-10
NO20171934A1 (en) 2017-12-05
HK1245078A1 (zh) 2018-08-24
AU2016258198A1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
MX2017014192A (es) Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa.
TW201713341A (en) Compositions and methods of treating a neurodegenerative disease
PH12017501046A1 (en) Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12016501457B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MX2018006223A (es) Moduladores de ror-gamma.
TW201613872A (en) IRAK4 inhibiting agents
MX2018009257A (es) Derivados de benzimidazol como moduladores de ror-gamma.
NZ737399A (en) Ccr2 modulators
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
MX2017011206A (es) Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer.
PH12016502353A1 (en) Pharmaceutical composition
MX2018004664A (es) Antagonistas de ep4.
PH12016502352A1 (en) Pharmaceutical composition
MX2017005484A (es) Compuestos antagonistas del receptor de dopamina d3.
MX2020011668A (es) Antagonistas duales de receptores de neurocinina-1 (nk-1)/neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales.
MX2017013877A (es) Compuestos de benzimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
PH12016501483B1 (en) P-substituted asymmetric ureas and medical uses thereof
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
PH12017501736A1 (en) Indole derivatives
MX2017008497A (es) Nuevos compuestos heterocíclicos y su uso tanto en medicina como en cosmética.